Literatur zu Kapitel 3.5: Tumormarker des malignen Melanoms

 Druckversion

Autor/en: S. Ugurel
Letzte Änderung: 01.12.2006

• Banfalvi T et al.
  Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
  Pathol Oncol Res 2002;8:183-187.




• Blesch A et al.
  Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA.
  Cancer Res 1994;54:5695-5701.




• Bogdahn U et al.
  Autocrine tumor cell growthinhibiting activities from human malignant melanoma.
  Cancer Res (1989), 49;5358-5363.




• Bosserhoff AK et al.
  Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma.
  Cancer Res 1997;57:3149-3153.




• Brossart P et al.
  Hematogenous spread of malignant melanoma cells in different stages of disease.
  J Invest Dermatol 1993;101:887-889.




• Deichmann M et al.
  Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase.
  Br J Cancer 2004;91:699-702.




• Deichmann M et al.
  Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma.
  J Exp Clin Cancer Res 2000;19:301-307.




• Deichmann M et al.
  S100-beta, melanomainhibiting activity and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
  J Clin Oncol 1999;17:1891-1896.




• Dietz UH, Sandell LJ.
  Cloning of a retinoic acidsensitive mRNA expressed in cartilage and during chondrogenesis.
  J Biol Chem 1996;271:3311-3316.




• Garbe C, Schadendorf D.
  Malignes Melanom - Neue Daten und Konzepte zur Nachsorge.
  Dtsch Ärztebl 2003;100:1804-1808.




• Ghanem G et al.
  On the release and half-life of S100B protein in the peripheral blood of melanoma patients.
  Int J Cancer 2001;94:586-590.




• Guo HB et al.
  Clinical significance of serum S100 in metastatic malignant melanoma.
  Eur J Cancer 1995;31A:924-928.




• Haimoto H, Hosoda S, Kato K.
  Differential distribution of immunoreactive S100-alpha and S100-beta proteins in normal nonnervous human tissues.
  Lab Invest 1987;57:489-498.




• Hauschild A et al.
  Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.
  Br J Dermatol 1999a;140:1065-1071.




• Hauschild A et al.
  S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.
  Oncology 1999b;56:338-344.




• Jury CS, McAllister EJ, MacKie RM.
  Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
  Br J Dermatol 2000;143:269-274.




• Moore BW.
  A soluble protein characteristic of the nervous system.
  Biochem Biophys Res Commun 1965;19:739-744.




• Mouawad R et al.
  Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.
  Clin Cancer Res 1996;2:1405-1409.




• Nakajima T et al.
  An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues.
  Am J Surg Pathol 1982;6:715-727.




• Persson L et al.
  S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system.
  Stroke 1987;18:911-918.




• Rebmann V et al.
  Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients.
  Int J Cancer 2002;100:580-585.




• Reinhold U et al.
  Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology Group.
  J Clin Oncol 2001;19:1723-1727.




• Seiter S et al.
  Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR.
  Recent Results Cancer Res 2001;158:105-112.




• Smith B et al.
  Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction.
  Lancet 1991;338:1227-1229.




• Sonesson B et al.
  Tyrosinase activity in the serum of patients with malignant melanoma.
  Melanoma Res 1995;5:113-116.




• Stahlecker J et al.
  MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
  Anticancer Res 2000;20:5041-5044.




• Ugurel S et al.
  Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
  J Clin Oncol 2001a;19:577-583.




• Ugurel S et al.
  Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
  Clin Cancer Res 2001b;7:1282-1286.




• Vuoristo MS.
  Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma.
  Eur J Cancer 2001;37:1629-1634.

Herausgeber: Prof. Dr. H. Link
Herausgeberbeirat: Prof. Dr. P. Albers, Prof. Dr. R. Andreesen, Priv.-Doz. Dr. A. Böhme, Prof. Dr. C. Bokemeyer, Prof. Dr. U. Creutzig, Prof. Dr. G. Ehninger, Prof. Dr. M. Freund, Prof. Dr. C. Garbe, Dr. N. Gökbuget, Prof. Dr. M. Hallek, Prof. Dr. J.T. Hartmann, Prof. Dr. R. Hehlmann, Prof. emerit. Dr. H. Heimpel, Prof. Dr. A. Hochhaus, Prof. Dr. K. Höffken, Dr. G. Hübner, Prof. Dr. Th. Junginger, Priv.-Doz. Dr. U. Kaiser, Priv.-Doz. Dr. R. Kath, Prof. Dr. C.-H. Köhne, Dr. R. Mahlberg, Prof. Dr. A. Matzdorff, Prof. Dr. R.-P. Müller, Prof. Dr. J. Preiß, Prof. Dr. H.-J. Schmoll, Prof. Dr. G. von Minckwitz